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VALIDATION AND COMPARISON OF THREE SAMPLE PREPARATION 
TECHNIQUES FOR QUANTITATION OF AMOBARBITAL, BUTALBITAL 
AND PHENOBARBITAL IN BLOOD AND URINE USING UFLC-MS/MS 
 
CHI HIN CHAN 
ABSTRACT 
 This research study successfully completed three objectives: 1) validate liquid-
liquid, supported-liquid, and solid-phase extractions for the quantitation of three 
barbiturates (amobarbital, butalbital, and phenobarbital) in blood and urine using liquid 
chromatography-tandem mass spectrometry; 2) to compare the efficiency and effectiveness 
among methods in accomplishing extraction of barbiturates under the laboratory setting at 
Boston University School of Medicine; and 3) to report all the analytical data to RTI 
International for interlaboratory comparison.  
For the validation study, a six-point linear calibration model (20-2000 ng/mL) with 
inversely weighted concentration (
1
𝑥
) was reproducible in all three sample preparation 
methods for both blood and urine with r2 greater than or equal to 0.994. Bias and precision 
evaluated from three controls throughout the range of the curve were both within ±20% 
and ±20%CV, respectively. Neither carryover nor interference was observed. Detection 
limits were evaluated down to 5 ng/mL depending on the extraction procedure. Samples 
were able to be diluted up to 50 times prior to instrumental analysis. Samples were stable 
on autosampler at room temperature up to 72 hours after their initial analysis. Recovery of 
vii 
barbiturates from blood and urine all ranged from 45% to 86%. The effect of ionization 
suppression or enhancement was found to have minimal impact on the validation.  
For choosing the most suitable method quantifying barbiturates, efficiency and 
effectiveness were studied. Efficiency evaluates the time and ease of sample preparation 
required to prepare a sample for analysis. Supported-liquid extraction was found to be the 
most efficient method for extracting barbiturates as it required the least amount of time to 
perform and could be easily automated with minimal training. Effectiveness is an 
assessment of one’s ability to selectively recover target analyte at a reasonably low 
concentration. By considering a method’s recovery, extract cleanliness, detection limits, 
and reproducibility, liquid-liquid extraction was the best at quantifying barbiturates in 
blood and supported-liquid extraction was the most suitable method for extracting 
barbiturates from urine. 
For interlaboratory comparison, all the data collected has been reported to RTI 
International. These findings can be used for examining the overall reliability and 
reproducibility of the validated methods. Results obtained can also be used to explore the 
possibility for streamlining sample preparation in the forensic laboratory, and hence 




TABLE OF CONTENTS 
 Page 
Title Page i 
Reader’s Approval Page iii 
Acknowledgments iv 
Abstract vi 
Table of Contents viii 
List of Tables xii 
List of Figures xvii 
List of Abbreviations xix 
1. Introduction 1 
1.1 History, Discovery, and Current Trends 1 
1.2 Recreational Use and Scheduling 4 
1.3 Chemical Properties 6 
1.3.1 Chemical Structures 6 
1.3.2 Acidity 8 
2. Sample Preparation 9 
2.1 Matrix Composition 11 
2.2 pH and pKa 13 
2.3 Polarity 15 
3. Research Objective 16 
4. Materials and Methods 19 
ix 
4.1 Chemicals and Reagents 19 
4.2 Liquid-Liquid Extraction (LLE) 21 
4.2.1 Principle 21 
4.2.2 Procedure 23 
4.3 Supported-Liquid Extraction (SLE) 24 
4.3.1 Principle 24 
4.3.2 Procedure 26 
4.4 Solid-Phase Extraction (SPE) 27 
4.4.1 Principle 27 
4.4.2 Procedure 31 
4.5 Liquid Chromatography – Tandem Mass Spectrometry (LC-
MS/MS) 
32 
4.5.1 Principle 32 
4.5.2 Hardware and Software  35 
4.5.3 Parameters 35 
5. Method Validation 38 
5.1 Calibration Model 39 
5.2 Carryover  40 
5.3 Detection Limits 41 
5.4 Bias and Precision 43 
5.5 Stability  45 
5.6 Dilution Integrity 46 
x 
5.7 Interference Studies 47 
5.8 Ionization Suppression/Enhancement 49 
5.9 Recovery 51 
6. Results and Discussion 52 
6.1 Liquid-Liquid Extraction (LLE) 52 
6.1.1 Calibration Model, Carryover, and Detection Limits 52 
6.1.2 Bias and Precision, Stability, and Dilution Integrity 55 
6.1.3 Interference Studies 57 
6.1.4 Ionization Suppression/Enhancement and Recovery 59 
6.2 Supported-Liquid Extraction (SLE) 61 
6.2.1 Calibration Model, Carryover, and Detection Limits 61 
6.2.2 Bias and Precision, Stability, and Dilution Integrity 63 
6.2.3 Interference Studies 65 
6.2.4 Ionization Suppression/Enhancement and Recovery 67 
6.3 Solid-Phase Extraction (SPE) 69 
6.3.1 Calibration Model, Carryover, and Detection Limits 69 
6.3.2 Bias and Precision, Stability, and Dilution Integrity 71 
6.3.3 Interference Studies 73 
6.3.4 Ionization Suppression/Enhancement and Recovery 75 
7. Comparisons 77 
7.1 Efficiency 77 
7.2 Effectiveness 79 
xi 
8. Conclusions 83 
8.1 Summary and Significance of Findings 83 
8.2 Future Directions 85 
Bibliography 86 
Curriculum Vitae 88 
  
xii 
LIST OF TABLES 
 Page 
Table 1.  Duration of Action and Scheduling for Common Barbiturates 5 
Table 2.  Change of Medium pH in Relation to the Percent Ionization of 
Weakly Acidic Drug 
14 
Table 3.  Change of Medium pH in Relation to the Percent Ionization of 
Weakly Basic Drug 
14 
Table 4. Auto-Sampler (SIL-20ACHT) Parameters 36 
Table 5. Time Program for Gradient Elution 36 
Table 6. Precursor and Product (Quantifying and Qualifying) Ions for Each 
Barbiturates and IS in MRM Mode 
37 
Table 7. Thirty-Nine Common Drugs of Abuse Tested for Interference at 2000 
ng/mL 
48 
Table 8. Individual and Average r2 for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using LLE 
53 
Table 9. LOD and LOQ for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using LLE 
55 
Table 10. Bias (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using LLE 
55 
Table 11. Within-Run Precision (%CV) for Amobarbital, Butalbital, and 




Table 12. Between-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using LLE 
56 
Table 13. Bias (%) for Average Response Ratio for Amobarbital, Butalbital, 
and Phenobarbital Stability in Blood and Urine Using LLE 
57 
Table 14. Bias (%) for Amobarbital, Butalbital, and Phenobarbital Diluted in 
Blood and Urine Using LLE 
57 
Table 15. Between-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital Diluted in Blood and Urine Using LLE 
57 
Table 16. Matrix Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using LLE 
58 
Table 17. Internal Standard Interference for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using LLE 
58 
Table 18. Common Analytes Interference for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using LLE 
59 
Table 19. Ionization Suppression/Enhancement (%) for Amobarbital, 
Butalbital, and Phenobarbital in Blood and Urine Using LLE 
60 
Table 20. Recovery (%) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using LLE 
60 
Table 21. Individual and Average r2 for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SLE 
61 
Table 22. LOD and LOQ for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
63 
xiv 
Table 23. Bias (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using SLE 
63 
Table 24. Within-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SLE 
64 
Table 25. Between-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SLE 
64 
Table 26. Bias (%) for Average Response Ratio for Amobarbital, Butalbital, 
and Phenobarbital Stability in Blood and Urine Using SLE 
65 
Table 27. Bias (%) for Amobarbital, Butalbital, and Phenobarbital Diluted in 
Blood and Urine Using SLE 
65 
Table 28. Between-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital Diluted in Blood and Urine Using SLE 
65 
Table 29. Matrix Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
66 
Table 30. Internal Standard Interference for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SLE 
66 
Table 31. Common Analytes Interference for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SLE 
67 
Table 32. Ionization Suppression/Enhancement (%) for Amobarbital, 
Butalbital, and Phenobarbital in Blood and Urine Using SLE 
67 
Table 33. Recovery (%) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
68 
xv 
Table 34. Individual and Average r2 for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SPE 
69 
Table 35. LOD and LOQ for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
71 
Table 36. Bias (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using SPE 
71 
Table 37. Within-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SPE 
72 
Table 38. Between-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SPE 
72 
Table 39. Bias (%) for Average Response Ratio for Amobarbital, Butalbital, 
and Phenobarbital Stability in Blood and Urine Using SPE 
73 
Table 40. Bias (%) for Amobarbital, Butalbital, and Phenobarbital Diluted in 
Blood and Urine Using SPE 
73 
Table 41. Between-Run Precision (%CV) for Amobarbital, Butalbital, and 
Phenobarbital Diluted in Blood and Urine Using SPE 
73 
Table 42. Matrix Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
74 
Table 43. Internal Standard Interference for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SPE 
74 
Table 44. Common Analytes Interference for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SPE 
75 
xvi 
Table 45. Ionization Suppression/Enhancement (%) for Amobarbital, 
Butalbital, and Phenobarbital in Blood and Urine Using SPE 
75 
Table 46. Recovery (%) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
76 
Table 47. Comparison of the Efficiency of LLE, SLE, and SPE 78 
Table 48. Comparison of Effectiveness of LLE, SLE, and SPE in Extracting 
Amobarbital from Blood and Urine 
81 
Table 49. Comparison of Effectiveness of LLE, SLE, and SPE in Extracting 
Butalbital from Blood and Urine 
81 
Table 50. Comparison of Effectiveness of LLE, SLE, and SPE in Extracting 
Phenobarbital from Blood and Urine 
82 
Table 51. Recommendations of Sample Preparation Method for the Extraction 





LIST OF FIGURES 
 Page 
Figure 1. Synthesis of Barbituric Acid From Malonic Acid and Urea With 
the Loss of Water 
1 
Figure 2. General Structure of Barbiturates (Ra, Rb = alkyl, allyl, or 
aromatic) 
7 
Figure 3. Reactive α-hydrogen on Barbituric Acid and Resonance 
Stabilization of the Resulting Aromatic Conjugated System 
7 
Figure 4. Structures of (A) Amobarbital, (B) Butalbital, and (C) 
Phenobarbital 
7 
Figure 5. Resonance Stabilization of Barbiturate Conjugate Base  8 
Figure 6. Selectivity and Cleanliness of Various Sample Preparation 
Techniques  
10 
Figure 7. Composition of Human Blood 12 
Figure 8. Composition of Human Urine 12 
Figure 9. Polarity of Different Functional Groups of Organic Compounds  15 
Figure 10. H-Bond Interactions Between Ethyl Acetate and Barbiturate 23 
Figure 11. Load-Wait-Elute Procedure for SLE 25 
Figure 12. H-Bond Interactions Between DCM and Barbiturate 25 
Figure 13. Structures of Hydrophilic-Lipophilic Balanced (HLB) 
Copolymers 
30 
Figure 14. Three-Step and Two-Step Procedures Waters HLB Cartridge 31 
xviii 
  
Figure 15. Total Ion Chromatogram Showing the Approximate Retention 
Times for Each Barbiturate and Respective Internal Standard 
37 
Figure 16. Standardized Residual Plots for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using LLE 
54 
Figure 17. Standardized Residual Plots for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SLE 
62 
Figure 18. Standardized Residual Plots for Amobarbital, Butalbital, and 





LIST OF ABBREVIATIONS 
AAFS American Academy of Forensic Sciences  
ACN Acetonitrile 
Amo Amobarbital 
ASB American Academy of Forensic Sciences Standards Board 
BUMC Boston University School of Medicine 
Butal Butalbital 
CFS Center of Forensic Sciences 
CNS Central Nervous System 
CSA Controlled Substances Act 
DCM Methylene Chloride 
DEA Drug Enforcement Administration 
ESI Electrospray Ionization 
HLB Hydrophilic-Lipophilic Balanced 
H-bond Hydrogen Bond 
IS Internal Standard 
LC Liquid Chromatography  
LC-MS/MS Liquid Chromatography – Tandem Mass Spectrometry  
LLE Liquid-Liquid Extraction 
LOD Limit of Detection  






MS Mass Spectrometry 
MS/MS Tandem Mass Spectrometer  
m/z mass-to-charge 
Na2HPO4 Sodium Phosphate Dibasic Anhydrous  
NaH2PO4·H2O Sodium Phosphate Monobasic Monohydrate 
ng Nanogram 
Pheno Phenobarbital 
R Correlation Coefficient 
r2 Coefficient of Determination 
RTI RTI International 
Si-OH Silanol 
SLE Supported-Liquid Extraction 
SPE Solid-Phase Extraction 
SWGTOX Scientific Working Group on Forensic Toxicology 
T0 Time zero at initial analysis 
T24 Twenty-four hours after initial analysis 
T48 Forty-eight hours after initial analysis 
T72 Seventy-two hours after initial analysis 
UCT United Chemical Technologies 
xxi 





1.1 History, Discovery, and Current Trends 
Barbiturates are a class of drugs that act as a nervous system (CNS) depressant. 
They were vastly used as sedative, hypnotic, anticonvulsant/ antiepileptic, and anesthetic 
drugs in the 20th century1. The discovery of this drug can be traced back to the synthesis of 
barbituric acid (or malonylurea) from malonic acid and urea in 1864 (Figure 1)2 by Adolf 
von Baeyer. In 1905, Baeyer was awarded the Nobel Prize in Chemistry for his work on 
organic dyes and hydroaromatic compounds in 1905.3 Barbituric acid itself has no medical 
value, yet, in the process of development during the early 20th century to synthesize 
compounds for medical use, modifications to the novel substance were extensive, thus 
leading to the start of the entire barbiturate era.  
 
 







The first barbiturate that made its way onto the market was 5,5-diethylbarbituric 
acid, also known as barbital or Veronal®.1 It was found to have sedative, hypnotic, and 
anticonvulsant properties and was on clinical trial for the treatment of sleeping disorders 
in 1904.1 However, phenobarbital, released in 1912 with the brand name Luminal®, was 
actually the first drug effective for psychiatric medication.1 Compared to its predecessors, 
such as alcohol, paraldehyde, chloral hydrate, bromide or Veronal® , phenobarbital is more 
potent in inducing sleep, which let to its clinical prevalence of being used for insomnia or 
sleeping disorder therapy.1 In addition, the sedative effect of phenobarbital also comes with 
an anticonvulsant action able to reduce the severity of seizures. As a result, phenobarbital 
became one of the first drugs for treating epilepsy in the early 20th century.4  
The success of phenobarbital did not stop the development of new drugs. Research 
on creating new barbiturates by the slight modification of barbituric acid continued. In the 
early to mid-20th century, more than 2500 barbiturates were synthesized and approximately 
50 of them made their way to the clinical market, including amobarbital, marketed as 
Amytal®, in 1923.4 Between 1920 to the mid 1950s, with a peak during the 1940s, 
barbiturates were practically the only drug used as sedatives and hypnotics for clinical 
purposes.1 Some of these compounds were also used for treating neurosis and psychosis.1 
Although the use of barbiturates was common, they did have some disadvantages. 
Psychiatrists or physicians at that time did not consider the adverse side effects that 
barbiturate medications might have, such as their synergistic effects, chance for addiction 
and overdose death.1 In the mid-20th century, the lack of health policy and drug monitoring 




introduction of benzodiazepines in the 1950s, also a group of sedative and anticonvulsants 
but with a greater margin of safety.4 With a safer substitute available, the gradual adoption 
of benzodiazepines for medication began, resulting in the continuous decline in the number 
of prescriptions for barbiturates over the mid to late-20th century. 
Today, only 12 types of barbiturates are used for therapeutic purposes.5 
Phenobarbital, in particular, is still a prevalent option as a sedative for treating 
gastrointestinal and asthmatic functional disorders.1 Although barbiturates are less 
commonly prescribed, they are still abused and detected in forensic cases. Detection 






1.2 Recreational Use and Scheduling 
 Although barbiturates have been greatly replaced by benzodiazepines for 
therapeutic purposes, they are still a prevalent choice of abuse among the public. 
Barbiturates are mainly classified based on duration of action: long-acting, intermediate-
acting, short-acting, and ultra-short acting (Table 1).1 Recreational users usually prefer 
short or intermediate-acting barbiturates, such as amobarbital and secobarbital.5 However, 
because of its small threshold between therapeutic and lethal dose, barbiturate overdose 
can occur. In response to this threat to public health, many barbiturates have been 
scheduled by the Drug Enforcement Administration (DEA) under the Controlled 
Substances Act (CSA).5 Scheduling a drug under the CSA requires an evaluation of the 
drug according to three criteria: medical use, potential for abuse, and potential for 
psychological or physical dependence.4 Since there are still 12 types of barbiturates used 
for medical purposes, they can only be scheduled within Schedule II to V due to their high 
potential for abuse and dependence. Currently, barbiturates are categorized as Schedule II, 
III, and IV depressants under the CSA (Table 1).5 These schedules apply to all forms of 
barbiturates that exists regardless of whether they come in as pill, capsule, tablet, injectable 









Table 1. Duration of Action and Scheduling for Common Barbiturates 
Barbiturate Brand/Trade Name Duration of Action Schedule 
Phenobarbital Luminal® Long IV 
Amobarbital Amytal® Intermediate II 
Butalbital Fiorinal® Intermediate III 
Pentobarbital Nembutal® Short II 
Secobarbital Seconal® Short II 






1.3 Chemical Properties 
1.3.1 Chemical Structures 
Barbiturates are a modification of barbituric acid and have both hydrophilic and 
hydrophobic characteristics. Its hydrophilicity depends on the three carbonyl groups (-
C=O) and the substituents (-H or -CH3) at N1 and N3 positions, while additions at C5 
position determine its hydrophobicity (Figure 2).6 However, barbiturates are synthesized 
predominantly by having modifications at the barbituric acid C5 position at which the α-
carbon has high tendency to release a proton (H+) due to the resulting resonance 
stabilization by the aromatic conjugated system (Figure 3).2 This reactive α-hydrogen 
allows various alkyl or aromatic additions to the barbituric acid, hence the formation of 
different barbiturates (Figure 3), including amobarbital (Amo), butalbital (Butal), and 
phenobarbital (Pheno) (Figure 4). Countless barbiturates have been created over the years 
using this process and the structure-activity relationship has therefore been extensively 
studied.2 Different substituents at the C5 position can generate different actions. For 
example, increasing the length of the aliphatic chain (hydrophobicity) could increase the 
potency of barbiturate yet decrease its duration of activity; and extending the chain on 







Figure 2. General Structure of Barbiturates (Ra, Rb = alkyl, allyl, or aromatic) 
 
 
Figure 3. Reactive α-hydrogen on Barbituric Acid and Resonance Stabilization of the 
Resulting Aromatic Conjugated System 
                   






Barbiturates, unlike most of the modern drugs, are acidic. Its acidity originates from 
the proton (H+) attached to the nitrogen atoms at positions 1 and 3 on the 2,4,6-
pyrimidinetrione backbone.6 The resonance stabilization when losing a proton makes them 
weak acids (Figure 5). Any substituent on a barbiturate disrupting this electron delocalizing 
system would decrease that acidity. The relative acidity of different barbiturates can 
therefore be ranked. Barbituric acid, despite the absence of medical value, is the most acidic 
compound among this category because it has no substituent. Addition at position C5 
similar to those on amobarbital, butalbital, and phenobarbital (Figure 4) makes barbiturate 
a weaker acid because the alkyl group (electron-donating group) disrupts the electron 
delocalization by inductive effect. The same goes for the nitrogen atoms at position 1 and 
3. Acidity decreases if one of the hydrogens connected to the nitrogen is substituted, while 
barbiturate is non-acidic if both the protons on the nitrogen atoms are eliminated.6 The 
acidity also makes barbiturate possible to be dissolved in water. This can be done by first 
reacting acidic barbiturate with a strong base. The resulting, salt form is water-soluble. 
 
 




2. SAMPLE PREPARATION 
 Sample preparation is a common pretreatment step for instrumental analysis. It is 
optional in some disciplines or laboratories, where techniques such as the dilute-and-shoot 
method are used, yet in forensic toxicology, it is often an essential step for analysis. 
Forensic toxicology laboratories usually receive biological cases related to death 
investigations or other criminal events such as driving under the influence or drug 
facilitated sexual assault. To analyze drugs in biological matrices, direct injection of 
sample into the instrument will often not generate useful results because matrix 
components may interfere with analyte detection, resulting in low sensitivity and recovery 
of the target compound. It may also damage analytical instruments or contaminate 
instrument parts. Removal of biological matrices and other unwanted materials (i.e., 
obtaining clean target analyte) through sample preparation is therefore necessary for 
analyzing samples in most forensic toxicology cases.7 
 Various sample preparation techniques are available, ranging from non-selective 
methods providing less clean extract to highly selective technology offering great analyte 
recovery (Figure 6). Which technique to use is usually a choice of the laboratory but the 
rationale behind selection is always a consideration of three basic aspects: matrix 












2.1 Matrix Compositions 
 To extract target analyte(s) out of the biological matrix, knowledge of the 
composition of each matrix is essential. Human blood and urine are the two most 
commonly encountered biological matrices in forensic toxicology casework. Blood is a 
composition of cellular elements (~45%) and plasma (~55%). Cellular elements consist of 
red blood cells (erythrocytes), white blood cells (leukocytes), and platelets, while plasma 
contains mainly water (~92%), salts, plasma proteins and other materials transported by 
blood, such as nutrients, wastes, respiratory gases, and hormones (Figure 7).7 Urine is 
composed of mostly water (~95%) with other metabolic by-products, such as urea, uric 
acid, creatinine, and various electrolytes (Figure 8).7 Since blood and urine are mainly 
water, while most of the drugs of abuse today are organic compounds,2 the selection of 
proper sample preparation technique will need to take this aqueous-organic relationship 






Figure 7. Composition of Human Blood 
 
 





2.2 pH and pKa 
 Drugs of abuse can be acidic, neutral, or basic. Their acidity (or basicity) may be 
described by a drug’s pKa values. Acidic drugs have low pKa values while basic drugs have 
high pKa (low pKb) values. The pKa value of a drug also determines the ionization state of 
the drug under different pH conditions according to the Henderson-Hasselbalch equation:  








A drug is 50% ionized (or dissociated) and 50% non-ionized (or neutral) when the pH of 
its surrounding environment equals to the pKa of the drug. Altering each pH unit of the 
environment will affect the concentration ratio of the ionized and non-ionized drugs by a 
factor of 10. A two-unit difference between environmental pH and drug’s pKa will lead to 
an almost 100% ionization or neutralization of the drug depending on its acidity (Table 2) 
or basicity (Table 3). The pKa of drug is therefore a crucial factor to be considered when 
choosing a sample preparation method because proper pretreatment can determine the 
ionization state of a target drug, and hence its efficiency of separating analyte(s) from other 








Table 2. Change of Medium pH in Relation to the Percent Ionization of Weakly Acidic 
Drug 
Medium pH [A-]/[HA] 
Percent of Ionized 
Acidic Drug (%) 
Percent of Unionized 
Acidic Drug (%) 
pKa + 2 100:1 ~99 ~1 
pKa + 1 10:1 90 10 
pKa 1:1 50 50 
pKa ‒ 1 1:10 10 90 
pKa ‒ 2 1:100 ~1 ~99 
 
Table 3. Change of Medium pH in Relation to the Percent Ionization of Weakly Basic Drug 
Medium pH [B]/[BH+] 
Percent of Ionized 
Basic Drug (%) 
Percent of Unionized 
Basic Drug (%) 
pKa + 2 1:100 ~1 ~99 
pKa + 1 1:10 10 90 
pKa 1:1 50 50 
pKa ‒ 1 10:1 90 10 







 Nearly all the drugs encountered today, as mentioned in section 2.1, are organic 
compounds.2 Their chemical structures vary with different functional groups and thus 
possess different degree of polarity (Figure 9). Polar compounds have a higher affinity 
towards polar medium over the non-polar medium due to the stronger intermolecular force 
(dipole-dipole interaction) existing in between. Compounds with functional groups 
containing electronegative atoms (e.g., oxygen, nitrogen) can even form hydrogen bonds 
(H-bond) with other compounds in an aqueous environment. The polarity of an analyte is 
therefore another important factor to be considered when selecting a sample preparation 
method as it affects the extraction efficiency of that drug from the sample mixture. 
 




3. RESEARCH BACKGROUND AND OBJECTIVE  
Drug-related death is currently one of the biggest challenges faced by the United 
States. Requests for toxicological analysis arrive every day at forensic laboratories. With 
limited resources and analysts, cases received by a laboratory are usually not handled 
immediately but stored prior to analysis. As time goes by, more cases would be backlogged, 
hence creating a burden on the laboratory. To help tackle the backlog issue, outsourcing 
part of the forensic analysis to private laboratories or hiring more analysts are two possible 
solutions. Other means include utilizing efficient sample preparation methods or 
employing state-of-the-art instrumentation.  
Sample preparation methods in particular, have been researched and improved by 
manufacturers all along. Novel separation techniques emerging in recent years have been 
proven to offer greater sensitivity and faster analytical processes while maintaining analyte 
integrity. However, even with the potential to reduce case backlogs, many forensic 
laboratories are still reluctant to shift from traditional techniques to new methods. Common 
reasons for not initiating the change include the lack of time and resources to validate and 
optimize new method(s); the performance uncertainty of a new method for a specific drug 
or matrix; as well as the favor of traditional methods due to easily accessible literature 
evaluating protocols and effectiveness, despite their lengthy and time-consuming 
procedures. In response to these hindrances of change, Center of Forensic Sciences (CFS) 
at RTI International (RTI) has initiated a collaborative project with Boston University 
School of Medicine (BUMC) to help streamline sample preparation, and hence potentially 




The purpose of this collaborative project was to evaluate various sample 
preparation methods for the extraction of common drugs in different biological matrices. 
Liquid-liquid extraction (LLE), solid-phase extraction (SPE), and supported-liquid 
extraction (SLE) were chosen to compare the efficiency between traditional (LLE and SPE) 
and novel (SLE) extraction methods. The capability of a method to perform multi-analyte 
extraction is also worth consideration as often only small sample volumes are available for 
analysis. A minimum of 25 drugs and metabolites were therefore chosen from eight 
common drug classes for evaluation, i.e. sympathomimetic amines, antidepressants, 
barbiturates, designer drugs, hallucinogens, opiates, and miscellaneous, such as cocaine 
and PCP. Blood, urine, and oral fluid were selected as targeted matrices as they are the 
most commonly encountered biological matrices in forensic toxicology. 
Despite having the same analyte and testing method, discrepancy among analytical 
results always exist between laboratories. The variability can be attributed to the difference 
in operating conditions (e.g., instrumentation) or the involvement of human 
variables/inconsistency (e.g., manual extraction steps), etc. To take these interlaboratory 
differences into account, a comparative project between two laboratories was proposed and 
this was the purpose of the collaboration between RTI and BUMC. Each laboratory 
developed and validated sample preparation techniques for a selected group of drugs and 
matrices previously mentioned. In addition to the evaluation of method performance within 
one laboratory, analytical data collected from both laboratories will be used collaboratively 




used to explore the possibility for streamlining sample preparation methods in forensic 
laboratories, and hence potentially reducing case backlogs.  
This research study constitutes part of the BUMC collaborative project with RTI. 
The objectives of this specific study are to validate three different sample preparation 
methods (LLE, SLE, and SPE) for the quantitation of three barbiturates (amobarbital, 
butalbital, and phenobarbital) in blood and urine using liquid chromatography-tandem 
mass spectrometry (LC-MS/MS); to compare the efficiency and effectiveness between 
methods in accomplishing extraction of barbiturates under the laboratory setting at BUMC; 





4. MATERIALS AND METHODS 
4.1 Chemicals and Reagents 
 Amobarbital (Amo), Butalbital (Butal), Phenobarbital (Pheno) and their respective 
deuterated internal standards (IS) (Amo-d5, Butal-d5, and Pheno-d5) were purchased from 
Cerilliant Inc. (Austin, TX, USA). LC-MS grade methanol was purchased from Fisher 
Chemical (Waltham, MA, USA). Standards came in ampules at 1 mg/mL, while internal 
standards were at 100 µg/mL. Stock solution 1 was made up in methanol with all three 
barbiturates evaluated at 100,000 ng/mL. Stock solution 2 was made up in methanol with 
all three barbiturates evaluated at 10,000 ng/mL. Working calibration solutions 1-6 were 
made up in methanol using stock solutions 1 and 2 at 200, 500, 1500, 5,000, 10,000, and 
20,000 ng/mL. Working control solutions (low, medium, high) were made up in methanol 
using stock solution 1 at 600, 9,500, and 18,000 ng/mL. Working IS solution was made up 
in methanol with all deuterated barbiturates at 5,000 ng/mL. Blank human blood was 
obtained from Boston Medical Center (Boston, MA, USA), Biological Specialty 
Corporation (Colmar, PA, USA), Equitech Enterprises Inc. (Kerrville, TX, USA) and 
UTAK Laboratories Inc. (Valencia, CA, USA).  Human urine was obtained from donation 
through approved Institutional Review Board protocols (Boston University School of 
Medicine, Boston, MA, USA). LC-MS grade hexane, ethyl acetate, methylene chloride 
(DCM), and acetonitrile (ACN) were obtained from Fisher Chemical (Waltham, MA, 
USA). Formic acid was obtained from Sigma-Aldrich (St. Louis, MO, USA). Sodium 
phosphate dibasic anhydrous (Na2HPO4) and sodium phosphate monobasic monohydrate 




acetate was obtained from Fisher Scientific (Fair Lawn, NJ, USA). Water used was purified 





4.2 Liquid-Liquid Extraction (LLE) 
4.2.1 Principle 
 Liquid-liquid extraction is one of the traditional means used in chemistry to 
separate a target analyte from a mixture. It works by the partitioning of compounds in a 
mixture into two immiscible liquid phases based on their affinity or interaction with each 
phase. This process is usually enhanced by shaking or rocking the vessel to create larger 
surface area for reaching partition equilibrium. A successful LLE will have only the target 
analyte partitioned into one phase and the rest of the mixture into another phase. The two 
solvent phases appear as immiscible layers and based on their densities, the layer 
containing the target drug is separated out. In forensic toxicology, the most common 
scenario involving compound separation is the extraction of target drug from a biological 
matrix for analysis. Since most drugs are organic and biological matrices contain mainly 
aqueous ingredients as mentioned in Section 2.1, an aqueous-organic LLE can be used. It 
can be done by mixing the sample mixture with an aqueous phase, followed by the addition 
of organic solvent in which protein or cellular elements are insoluble.  
 To facilitate the partitioning of a drug from the aqueous layer into organic solvent, 
the non-ionic neutral form of drug is desired. This can be accomplished by having a buffer 
as the aqueous phase and adjusting its pH two units lower (higher) than the pKa of the 
acidic (basic) drug. If a target drug is neutral in nature, it can be extracted in all pH 
conditions (from 0 to 14).2 However, the extract may demand a further cleaning step as it 
is isolated passively by first removing the acid and base fractions of the mixture. The LLE 




amobarbital, butalbital, and phenobarbital are the target analytes. They are weakly acidic 
drugs and have pKa values between 7 to 9 (Figure 4). Phosphate buffer at pH 5 was 
therefore used as the aqueous phase to convert all ionized drug to their non-ionized form, 
hence ready the analytes for being extracted into the organic phase. 
 As mentioned in Section 2.3, most drugs possess different degrees of polarity. 
Adjusting the polarity of organic solvent in LLE can therefore improve the partition 
specificity, resulting in the extraction of the target drug out of the aqueous layer. This can 
be done by mixing a non-polar organic solvent, such as hexane, with other polar organic 
solvents that have the ability to donate (e.g., chloroform) or accept (e.g., diethyl ether) 
hydrogen in a H-bond. Alcohols (e.g. isopropanol, butanol) are a common choice for this 
practice as they can form H-bonds in either case. The proportion of each organic solvent 
in the mix is actually flexible. The ratio of solvents can be adjusted according to the polarity 
of the target compound. For example, 1-5% of isopropanol in hexane is effective in 
extracting phenothiazine from blood due to its chemical structure.2 In this study, 50% of 
ethyl acetate by volume in hexane was chosen to extract barbiturates. This was used 
because the oxygen atoms on ethyl acetate are able to form H-bonds with the hydrogen 
atoms at positions N1 and N3 on barbiturate (Figure 10).2 This can facilitate the partitioning 






Figure 10. H-Bond Interactions Between Ethyl Acetate and Barbiturate 
 
4.2.2 Procedure 
 To 200 µL of drug free blood or urine in a 7 mL screw top vial, 20 µL of IS was 
added (except for the double blank; sample with blank matrix only), followed by 0.5 mL 
of pH 5 phosphate buffer into all samples. After vortexing, 1.5 mL of extraction solvent 
(Hexane:Ethyl Acetate 50:50) was added into the solution. The vial was then capped, 
rocked for 10 minutes, and centrifuged at 3500 rpm for 5 minutes. The top organic layer 
was then transferred into a 15 mL test tube and was evaporated to dryness at 40ºC. Dried 






4.3 Supported-Liquid Extraction (SLE) 
4.3.1 Principle 
 Supported-liquid extraction is an emerging sample preparation technique analogous 
to aqueous-organic LLE. Similar to LLE, the separation works by the partitioning of target 
analyte and sample mixture into two immiscible phases.9 However, unlike increasing the 
partition interface by shaking or rocking in LLE, the contact surface area in SLE is 
enhanced by dispersing the liquid aqueous phase over a modified diatomaceous earth-based 
material in a cartridge. This material is designed with a network of pores. It is inert to 
sample and solvent, yet can retain the aqueous phase as small droplets and facilitate the 
formation of aqueous layer all over. When applying immiscible organic solvent into the 
cartridge, it flows through the material and comes in contact with the aqueous phase 
droplets on the surface. Partitioning of the target analyte and sample mixture between two 
phases therefore occurs over a large surface area supported by the material. Further 
addition of organic solvent through the sorbent bed allows partitioning to happen again, 
hence imitating a repeat LLE and maximizing the extraction.9  
 The extraction of a drug from biological matrix with SLE starts with buffering the 
sample to ensure the unionized form of the drug is achieved. The sample in aqueous buffer 
solution is then loaded into the cartridge and is waited to spread over the modified 
diatomaceous earth-based material. Applying organic solvent similar to that used in LLE, 
in which the protein and cellular elements of the matrix are insoluble, the drug can be eluted 
into a collection vessel for instrumental analysis (Figure 11). In this study, ammonium 




and phenobarbital (pKa values between 7 to 9) into their unionized forms. DCM was chosen 
as the elution solvent because its chlorine atoms can form H-bonds with the hydrogen 
atoms at positions N1 and N3 on barbiturate (Figure 12),2 therefore facilitating the partition 
of barbiturate into the organic phase. 
 
 
Figure 11. Load-Wait-Elute Procedure for SLE9 
 
 





 To 300 µL of blank blood or urine in a 6 mL test tube, 20 µL of IS was added 
(except for the double blank), followed by 300 µL of pH 5 ammonium acetate buffer (100 
mM) into all samples. After vortexing, sample was loaded into a Biotage ISOLUTE® SLE+ 
cartridge (1 mL sample volume) (Uppsala, Sweden) for extraction. A pulse of pressure was 
applied on the cartridge to initiate flow. After absorbing for 5 minutes, the sample was 
eluted by gravity into a 15 mL test tube with 2.5 mL of DCM. Elution was performed again 
into the same test tube after waiting for another 5 minutes. The extraction was then 
completed by applying a pulse of pressure on the cartridge. Sample collected in the test 
tube was evaporated to dryness at 40ºC. Dried sample was reconstituted in 100 µL of 





4.4 Solid-Phase Extraction (SPE) 
4.4.1 Principle 
 Solid-phase extraction, technically also known as liquid-solid phase extraction, is 
one of the most frequently used sample preparation methods today in the analytical 
laboratory. It originated from column chromatography that utilized the interaction with 
packing materials in a column for characterization.2 However, instead of using a large, tall 
glass column for chromatography, SPE utilizes a small cartridge or column packed with a 
specifically designed sorbent for separation. The goal of SPE is to first retain target analyte 
in cartridge; then remove unwanted components in the mixture; and later recover and 
concentrate target analyte by eluting through the column with a little solvent.2 The entire 
extraction will be most effective if the proper sorbent material chosen.  
 Common sorbents include bonded silica material and polymer. Bonded silica 
sorbent is made by joining the silicon atom or silanol group (Si-OH) on the surface of a 
refined silica particle covalently to selectively active groups.11 Polymer packing material, 
on the other hand, does not contain silica but of hydrocarbons incorporated with selectively 
active groups. Active groups are functional groups manufactured on a sorbent surface that 
selectively interact with a target analyte and hence influence retention as the analyte passes 
through the cartridge. These groups be hydrocarbon chain (e.g., C2, C4, C8, C18, phenyl 
group, etc.) for the extraction of non-polar analytes via non-polar intermolecular force, 
hydroxyl group (e.g., silanol or diol group) for retaining polar analytes,10 or anion/cation 
exchange site for ionized analytes.2 Anion exchange sites usually constitute positively 




analytes (negatively charged), while cation exchange sites are usually composed of 
negatively charged sulfonic acid or carboxylic acid for the extraction of ionized basic 
compounds (positively charged).10 In fact, sorbent materials (for both bonded silica and 
polymer) can possess more than one selectively active groups and when they do, they are 
regarded as mixed mode sorbents offering primary and secondary interactions with the 
sample.7 For example, a polymer sorbent can have a long hydrocarbon chain on one end 
and an anion exchange site on the other end, allowing it to extract acidic yet non-polar 
analytes from the sample mixture.10 What sorbent type used depends on the chemical 
properties of the analyte of interest and in forensic toxicology, drugs of abuse in biological 
matrix are common targets. Since most of the drugs, as mentioned in Sections 2.2 and 2.3, 
possess certain degrees of acidity (or basicity) and polarity at the same time, SPE cartridges 
containing a mixed mode sorbent is a popular choice for many forensic toxicology 
laboratories. 
 Regardless of the sorbent type used, many of the sorbents in SPE cartridges are 
extremely hydrophobic due to their silica or hydrocarbon-based composition. Target 
analytes, which are usually in aqueous phase (polar) after sample pretreatment, will not be 
retained in the sorbent at all even with the selective active groups available on the sorbent 
surface. Application of water-miscible organic solvent, such as methanol or ACN, into the 
cartridge to generate an interface for the hydrophobic sorbent and hydrophilic sample to 
interact is therefore essential.11 This constitutes the first step of the general five-step SPE 
procedure: condition, equilibrate, load, wash, and elute. The second step is to equilibrate 




on the sorbent surface are at desired state (e.g. ionization state of ion exchange site) for the 
retention of the target analyte and the release of unwanted materials. After the buffer has 
passed through and without drying the sorbent, similarly buffered pretreated sample can be 
loaded onto the cartridge. With the interaction between the active groups and the sample 
occurring over the sorbent, washing solvents can be used to selectively remove the 
undesired materials while leaving the target analyte unaltered. Once the contaminants are 
washed off, the target analyte can be separated by elution into a collection vessel. The 
elution solvent used in this final step should be able to specifically disrupt the retention 
interaction between the sorbent active groups and the target analyte, but also retain the 
unwanted material which may have endured the washing step.11  
 Although this five-step procedure is the general practice for SPE, some SPE 
cartridges neither require conditioning nor equilibrating steps, allowing a three-step or less 
SPE procedure. These cartridges are usually water-wettable, meaning in addition to the 
extremely hydrophobic structure and selective active groups, the sorbent incorporates 
hydrophilic groups as well. This hydrophilic group functions the same as the water-
miscible organic solvent added during the normal conditioning step, thus permitting 
interaction between hydrophobic sorbent and hydrophilic sample without conditioning or 
equilibrating the cartridge. Since the sorbent surface is already active with the water-
wettable cartridge, avoiding drying the sorbent bed during sample preparation is no longer 
a concern.11 
 The Waters (Milford, MA, USA) hydrophilic-lipophilic balanced (HLB) cartridge 




(lipophilic) polymers with hydrophilic groups on the surface (Figure 13),12 thus allowing 
the elimination of cartridge conditioning and equilibration (3-step procedure) steps. In 
addition to the 3-step procedure, this cartridge can also be used for a 2-step cleanup 
according to the manufacturer’s protocol (Figure 14).13 During the 2-step extraction, 
pretreated sample is first loaded into the cartridge. Target analyte is then eluted into a 
collection vessel while leaving the unwanted materials on the sorbent. In this study, a 2-
step procedure with an HLB cartridge was adopted for the extraction of barbiturates, yet 
two modifications were made. The first change was the addition of elution solvent (ACN) 
into the sample during pretreatment, thus combining the load and elution steps. The second 










Figure 14. Three-Step and Two-Step Procedures Waters HLB Cartridge13 
 
4.4.2 Procedure 
 To 200 µL of blank blood or urine in a 6 mL test tube, 20 µL of IS was added 
(except for double blank), followed by 1 mL of cold ACN into all samples. After vortexing, 
the samples were centrifuged at 4000 rpm for 5 minutes. Waters Oasis PRiME HLB 
cartridge (3cc, 60 mg) in a United Chemical Technologies (UCT) (Bristol, PA, USA) 
positive pressure manifold was utilized for extraction. The cartridge was conditioned by 
methanol (2 mL) and deionized water (2 mL). To the conditioned columns, sample was 
loaded and allowed to pass through by gravity, followed by positive pressure at 1 to 2 
mL/min, and quick full vacuum. Sample was collected in a 15 mL test tube and was 
evaporated to dryness at 40ºC. Dried sample was reconstituted in 100 µL of mobile phase 




4.5 Liquid Chromatography – Tandem Mass Spectrometry (LC-MS/MS) 
4.5.1 Principle 
Chromatography is a method using two phases, i.e. stationary phase and mobile 
phase, to separate components in a mixture. Liquid chromatography (LC) means liquid 
mobile phase is utilized for separation as well as identification.2 There are four basic 
components in an LC system. They are the solvent reservoirs, the pumps, the sample 
injector, and the LC column. The pumps are used to deliver mobile phase stored in solvent 
reservoirs and the sample from injector to the LC column.  
The LC column is where separation occurs and is packed with materials acting as 
the stationary phase. Stationary phase is usually relatively non-polar (while mobile phase 
is relatively polar) as most of the LC systems are operated in reversed phase. When the 
solvents (mobile phase) containing the sample mixture pass through the LC column 
(stationary phase), separation of the mixture begins. The entire separation works based on 
the differential affinity of target analyte towards the mobile phase and the stationary phase. 
If one component has higher affinity towards the mobile phase over the stationary phase, 
it will be eluted out of the column earlier and vice versa. The total time for an analyte to 
be retained in the column before being eluted out for detection is called the retention time. 
Retention time is usually specific to a particular analyte under the same chromatographic 
conditions. Identification using LC is therefore theoretically available.14 
For each component in a mixture to be eluted out of the LC column at a specific 
time, they have to be effectively resolved from one another to a certain degree. Apart from 




contaminants, effective separation can also be accomplished by having appropriate elution 
conditions. Isocratic elution and gradient elution are the two commonly used elution types 
for LC.14 Isocratic elution means only one solvent or a single composition of solvent 
mixture is used as mobile phase, while gradient elution is the use of two or more solvents 
with gradual change in composition over the course of a method. The latter is often 
preferred as mobile phase polarity can be adjusted easily by changing the composition of 
solvents. This allows fine separation of mixture components based on polarity to happen 
without the need to alter the LC column. Separation efficiency is therefore greatly enhanced.  
Mass spectrometry (MS) is a technique used to characterize and identify sample 
components in a mixture. The MS system consists of three major components: ion source, 
mass analyzer, and ion detector. When a sample is carried into the MS system, it is first 
fragmented and ionized by the ion source. Charged or ionized sample fragments will then 
be transferred to the mass analyzer where unique ions are selected and detected based on 
their mass-to-charge (m/z) ratio. A quadrupole mass spectrometer is the most common 
mass analyzer used for this purpose. It filters the fragment ions by altering the direct current 
and radio frequency voltages across four conduction rods. Only fragments with selected 
m/z ratio are allowed to reach the ion detector for detection. Since each component in a 
sample will have a unique fragmentation pattern under a specific MS condition, 
identification or characterization can be made by examining the resulting ionized fragments 
in the mass spectrum.14  
Electrospray ionization (ESI) is one of the common ion sources used to produce 




techniques are coupled together. ESI works by charging the liquid sample either positively 
or negatively during nebulization so that when undergoing evaporation, a sample will be 
fragmented automatically due to the extensive increase in charge density. Since ESI is a 
soft ionization technique, most of the samples will remain intact without fragmentation 
after ionization. Tandem mass spectrometers (MS/MS) are common mass analyzers used 
in conjunction with LC, thus forming LC-MS/MS. In MS/MS, there are three quadrupole 
mass spectrometers. After receiving the ionized samples from the ion source, the first 
quadrupole detects the parent transition by isolating ions of interest for further 
fragmentation. Further fragmentation happens in the second quadrupole, also called the 
collision chamber. Ionized sample fragments will then be transferred into the third 
quadrupole and the ion detector for analysis. Ions selected by the first quadrupole are called 
precursor ions, while ions being analyzed at the third quadrupole are the product ions.14 
With the advantage of triple quadrupoles, multiple precursor ions from a sample and their 
respective product ions can be targeted and monitored, i.e. multiple reaction monitoring 
(MRM). This allows the identification of specific analytes from an unknown sample. 
Overall, LC-MS/MS is able to separate and identify target analyte from a sample. With the 







4.5.2 Hardware and Software  
All analyses were conducted using a Waters XBridge™ C18 LC column (3.5 μm 
particle size; 50 mm length; 2.1 mm internal diameter) on a Shimadzu Ultra-Fast Liquid 
Chromatograph (UFLC) coupled to a SCIEX 4000 QTRAP® MS/MS. The Shimadzu 
UFLC system consisted of a DGU-20A3R degassing unit, two LC-20AD pumps, a SIL-
20ACHT auto-sampler, a CTO-20A column oven, and a CBM-20A LC system controller 
(Kyoto, Japan). The SCIEX 4000 QTRAP® system contained a hybrid triple 
quadrupole/linear ion trap tandem mass spectrometry with a Turbo V™ source for ESI 
(Framingham, MA, USA). Data was collected by Analyst® Software (version 1.6.2), while 
statistical analysis was performed using MultiQuant™ Software (version 3.0.5373.0). 
 
4.5.3 Parameters 
Sample injection volume was 10 µL (Table 4) with the flow rate maintained at 0.6 
mL/minute. Column oven temperature was set at 40ºC throughout the analysis. The total 
sample run time was 6.5 minutes. Two mobile phases were used in this study and they were 
0.1% of formic acid in water (mobile phase A) and 0.1% of formic acid in ACN (mobile 
phase B). Gradient elution was utilized during the analysis, starting with 90% mobile phase 
A from the beginning to 90% mobile phase B at the end (Table 5). Approximate retention 
times for each barbiturate and their respective IS are showed in Figure 15. All samples 




and detected by the tandem mass spectrometer in MRM scanning mode. The precursor and 
product (quantifying and qualifying) ions for each barbiturate and IS are listed in Table 6. 
 
Table 4. Auto-Sampler (SIL-20ACHT) Parameters 
Rinsing Volume 1000 µL 
Rinsing Speed 35 µL/second 
Rinse Dip Time 5 seconds 
Needle Stroke 52 mm 
Sampling Speed 3.0 µL/second 
Purge Time 25 minutes 
Cooler Temperature 15°C 
Injection Volume 10 µL 
 
Table 5. Time Program for Gradient Elution 
Time (minute) Mobile Phase A (%) Mobile Phase B (%) 
0.01 90 10 
4 30 70 
5 10 90 
5.5 10 90 







Figure 15. Total Ion Chromatogram Showing the Approximate Retention Times for Each 
Barbiturate and Respective Internal Standard 
 
Table 6. Precursor and Product (Quantifying and Qualifying) Ions for Each Barbiturates 
and IS in MRM Mode 
Barbiturate and IS Precursor Ions 
Product Ions  
(Quantifying) 
Product Ions  
(Qualifying) 
Amobarbital 224.9 42.2 182.0 
Amobarbital-d5 229.9 42.0 187.0 
Butalbital 222.9 42.2 180.1 
Butalbital-d5 228.0 42.0 184.9 
Pentobarbital 225.0 42.0 181.7 








5. METHOD VALIDATION 
Method validation involves a set of experimental procedures performed to 
objectively demonstrate that a particular analytical method is valid and is fit for its purpose 
under normal laboratory conditions. It is also conducted to identify a method’s limitations 
before implementation of the actual casework analysis. Validation of a method is needed 
when a laboratory 1) intends to employ a new analytical method; 2) modifies an existing 
method for improvement; 3) evaluates equivalent performance between existing and new 
methods; and 4) needs to demonstrate an existing method is meeting newly establish 
criteria.15 The guidelines for validating an analytical method varies among different 
disciplines. In forensic toxicology, laboratories generally follow the American Academy 
of Forensic Sciences (AAFS) Standards Board (ASB) standard, which was originally 
drafted by the Scientific Working Group on Forensic Toxicology (SWGTOX)16 for method 
validation. This standard illustrates the parameters required for validation for each kind of 
analytical technique, as well as the minimum criteria for each validation parameter to be 
acceptable. As mentioned in section 3, the purpose of this study is to validate sample 
preparation methods for the quantitation of barbiturates in LC-MS/MS. The abilities of 
each sample preparation technique to extract and facilitate the detection and quantification 
of barbiturates need to be demonstrated. According to the ASB standard, ten parameters 
are required to be assessed to validate a quantitative method. They are calibration model, 
carryover, limit of detection (LOD), limit of quantification (LOQ), bias and precision, 
dilution integrity, stability, interference studies, ionization suppression or enhancement, 




5.1 Calibration Model  
Calibration model of a method is the working range of concentration in which a 
target analyte can be detected and quantified based on its response ratio (area of analyte 
over area of IS). It is evaluated by having at least six calibrators, preferably matrix-
matched, spanning across different non-zero concentrations over five separate runs. For 
each calibrator and control, the ion ratio (area of qualifying ion over area of quantifying 
ion) has to be within ±20% of the average ion ratio;17 and the calculated concentration 
against the calibration curve have to be within ±20% of the expected value. Coefficient of 
determination (r2), the square of correlation coefficient (r), and standardized residual plots 
are also the parameters to assess the calibration model. Any concentration calculated that 
lies outside ±3 standard deviation of the expected value will be treated as an outlier. In this 
situation, a transformation of variables, and hence the calibration model to other regression 
models maybe needed. 




) was desired. Matrix-matched calibrators at 20, 50, 150, 500, 1000 and 
2000 ng/mL; and controls at 60, 950 and 1800 ng/mL were prepared from working 
calibration solutions and working control solutions, respectively, for evaluation. Internal 
standard at 500 ng/mL prepared from working IS solution was also included in both 








Carryover means the appearance of preceding sample response on subsequent 
sample detection during instrumental analysis. It will lead to inaccurate results and 
therefore needs to be assessed. Carryover is usually assessed by evaluating a blank matrix 
sample immediately after a sample fortified at a high concentration. In this study, it was 
evaluated by running a double blank, blank matrix without internal standard, immediately 
after the highest calibrator of every calibration curve. Any signal higher than 10% of the 
lowest calibrator response observed in the double blank at the correct retention time was 







5.3 Detection Limits 
There are two types of detection limits: limit of detection (LOD) and limit of 
quantitation (LOQ). LOD indicates the lowest possible concentration at which an analyte 
can be detected, while LOQ expresses the lowest possible concentration at which an 
analyte can be detected and quantified. LOD can be evaluated using background noise by 
preparing at least three different blank matrices (double blanks) and fortified samples at 
decreasing concentrations in duplicate over three separate runs. A concentration level is 




greater than or equal to the average background noise of blank matrix (𝑋𝐵𝑙𝑎𝑛𝑘 𝑀𝑎𝑡𝑟𝑖𝑥) plus 
3.3 times of its standard deviation (𝑆𝐵𝑙𝑎𝑛𝑘 𝑀𝑎𝑡𝑟𝑖𝑥). expressed by the following formula: 
𝐿𝑂𝐷 = 𝑋𝐵𝑙𝑎𝑛𝑘 𝑀𝑎𝑡𝑟𝑖𝑥 + 3.3(𝑆𝐵𝑙𝑎𝑛𝑘 𝑀𝑎𝑡𝑟𝑖𝑥) 
and 2) is acceptable for other predefined criteria, such as ion ratio within ±20% of average, 
peak shape, ±5% retention time, etc.  
Limit of quantitation is usually evaluated concurrently with LOD by preparing at least three 
different blank matrices fortified at decreasing concentrations in duplicate over three 
separate runs. This approach requires concentrations to be within the previously established 
calibration model. Therefore, when attempting to quantify samples at a concentration lower 
than the lowest calibrator, control samples along those levels are needed. Similar to LOD, 
fortified samples need to meet the acceptable predefined criteria, including bias and 
precision (to be discussed in section 5.4), in order to be deemed as LOQ.  
In this study, three sets of blank matrices and their fortified samples at 5, 10, 15, 
and 20 ng/mL were analyzed in duplicate with controls at 10, 15, and 20 ng/mL over three 




5.4 Bias and Precision 
Bias (or accuracy) indicates how close the concentrations measured by a method 
are to their expected values, while precision is an indicator of how close the results are to 
each other. Bias and precision are usually evaluated together. This is done by analyzing 
three different samples per concentration at three concentration levels (low, medium, and 
high) over five separate runs. The low concentration should be at least 3 times the lowest 
calibrator; the high concentration should be at least 80% of the highest calibrator; and the 
medium concentration should be near the midpoint of the low and high controls. Bias for 
each concentration can be calculated by the following formula:  
𝐵𝑖𝑎𝑠 (%) 𝑎𝑡 𝑎 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
=  (
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 − 𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
) × 100% 
For precision, within-run and between-run precision is of interest for method validation. 
Within-run precision is the precision at each control replicate with each of the five runs. 
Between-run precision is the precision at each concentration over five runs. Precision is 
expressed by coefficient of variation (%CV) and calculated by the formula below: 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%𝐶𝑉) 𝑎𝑡 𝑎 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
=  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛  𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
 × 100% 
Within-run precision is calculated by:  
𝑊𝑖𝑡ℎ𝑖𝑛-𝑅𝑢𝑛 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%𝐶𝑉) 𝑎𝑡 𝑎 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
=  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛  𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑣𝑒𝑟 𝑎 𝑆𝑖𝑛𝑔𝑙𝑒 𝑅𝑢𝑛
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑣𝑒𝑟 𝑎 𝑆𝑖𝑛𝑔𝑙𝑒 𝑅𝑢𝑛




And between-run precision is calculated by: 
𝐵𝑒𝑡𝑤𝑒𝑒𝑛-𝑅𝑢𝑛 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 (%𝐶𝑉) 𝑎𝑡 𝑎 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
=  
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛  𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑣𝑒𝑟 𝐹𝑖𝑣𝑒 𝑅𝑢𝑛𝑠
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑣𝑒𝑟 𝐹𝑖𝑣𝑒 𝑅𝑢𝑛𝑠
 × 100% 
For a method to be acceptable, its bias, within-run and between-run precision at each 
concentration level have to be within ±20% or 20%CV, respectively. The ion ratio for each 
calculated concentration against the calibration curve needs to be within ±20% of the 
average ratio as well. 
In this study, bias and precision were evaluated concurrently by running matrix-
matched controls in triplicate per concentration over the three concentration levels in five 
separate runs. The concentrations for low, medium, and high controls were 60, 950 and 







There are circumstances in which samples may need to be re-analyzed a few days 
later after it was first extracted. Unforeseen situations include poor injection, carryover, 
instrumental error, etc. The length of time an extracted sample can stay unchanged at room 
temperature (i.e. in autosampler) before re-injection needs to be studied in order to evaluate 
method robustness. It is commonly assessed by preparing matrix-matched samples fortified 
at low and high concentrations in triplicate, followed by comparing the average response 
ratio (area of IS over area of analyte) of those analyzed immediately after sample 
preparation (time zero, T0) to that of those re-analyzed at regular intervals later. A sample 
is stable for re-analysis at certain times later only if the bias of average response ratio at 
that time point is within ±20%, which is calculated by the following formula: 
𝐵𝑖𝑎𝑠 (%) 𝑜𝑓 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑅𝑎𝑡𝑖𝑜 𝑎𝑡 𝑎 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
=  (
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑅𝑎𝑡𝑖𝑜 𝑎𝑡 𝑎 𝑇𝑖𝑚𝑒 𝑃𝑜𝑖𝑛𝑡 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑅𝑎𝑡𝑖𝑜 𝑎𝑡 𝑇𝑖𝑚𝑒 𝑍𝑒𝑟𝑜
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑅𝑎𝑡𝑖𝑜 𝑎𝑡 𝑇𝑖𝑚𝑒 𝑍𝑒𝑟𝑜
) × 100% 
The stability in this study was evaluated by also having matrix-matched controls in 
triplicate per concentration over three concentration levels, similar to the approach 
mentioned in section 5.4, yet re-injected at different times. The concentrations of controls 
were at 60, 950 and 1800 ng/mL. The time points for re-analysis were 24 hours (T24), 48 




5.6 Dilution Integrity 
Drugs detected in samples received by a laboratory can be at concentrations above 
the established limit of quantitation or with low sample volume which may require dilution. 
Dilution integrity is therefore an important factor to be assessed during method validation. 
This parameter is usually evaluated by monitoring the bias and precision of samples diluted 
at common dilution ratios, such as 1:2, 1:10, 1:50, etc., depending on the laboratory’s 
needs. Sample dilution at a particular ratio is only allowed if the bias, precision, and ion 
ratio are within the acceptable range, i.e., ±20%. 
In this study, blank matrix was first fortified at 4000 ng/mL to mimic a high 
concentration sample. Ten times (400 ng/mL) and fifty times (80 ng/mL) dilutions of the 
fortified sample were then prepared in triplicate over five separate runs for the assessment 




5.7 Interference Studies 
Common substances, such as components in matrix or other drugs, may generate 
signals interfering with those of the target analyte, hence affecting the specificity of a 
method. Signals from common sources can be deemed insignificant to signals from target 
analyte(s) but this needs to be demonstrated before method implementation. Three types 
of interferences are commonly assessed during method validation: matrix interference, IS 
interference, and interference from common analytes. Matrix interference is examined by 
looking at the signal responses of a minimum of 10 different blank matrices for each matrix 
type without the addition of IS. IS interference is evaluated by analyzing blank matrix 
individually fortified with IS at high concentration only and then blank matrix spiked with 
only target analyte at the upper end of calibration range. This is for the purpose of 
examining if the purchased IS contains target analyte or interfering ions, and vice versa. 
Interference from common analytes are assessed by looking at the signal responses of blank 
matrix fortified with other commonly encountered analytes (e.g., drugs of abuse, 
metabolites) at high concentrations without IS.  
In this study, 10 different lots of blank matrix without IS were used to assess matrix 
interference. For IS interference, matrix-matched samples fortified with IS only and the 
highest calibrator only were used. Interferences from common analytes were evaluated by 
having matrix-matched samples fortified separately at 2000 ng/mL with a total of 39 
different drugs classified into three groups (Table 7). For all types of interference, any 
signal greater than the LOD (IS and common analyte interferences) or LOQ (matrix 







Table 7. Thirty-Nine Common Drugs of Abuse Tested for Interference at 2000 ng/mL 
Intermix 1 (2000 ng/mL) 
Benzoylecogonine Clonazepam Cocaine Codeine Diazepam 
Etizolam Fentanyl Hydrocodone Lidocaine Methadone 
Morphine Norcocaine Oxycodone α-hydroxyalprazolam 6-acetylmorphine 
7-aminoclonazepam     
















Intermix 4 (2000 ng/mL) 
Amitriptyline Amphetamine Citalopram Ethylone Fluoxetine 
Lysergic acid 
diethylamide 


















5.8 Ionization Suppression/Enhancement 
Analyte signals may be subject to ionization suppression or enhancement by co-
eluting substances, such as biological matrices, when being analyzed by LC-MS with ESI. 
This parameter is therefore also called matrix effect. It is important to evaluate the matrix 
effect of a method to ensure such signal suppression or enhancement is within an 
acceptable range. Ionization suppression or enhancement evaluated by the post-extraction 
addition approach is a comparison of signal responses between the neat standard (target 
analyte alone neither matrix nor extraction) and the blank matrices fortified with target 
analyte after extraction. Since the target analyte in both types of samples does not undergo 
extraction, any change of the analyte signal would be solely the consequence of the 
presence or absence of matrix. This signal comparison will be conducted at two different 
concentrations (low and high). At one of the concentrations, the average signal response 
from injecting neat standard a minimum of six times will be compared to the average signal 
response from injecting at least 10 different blank matrices fortified with target analyte 
after extraction in duplicate. The ionization suppression or enhancement at a concentration 
can then be calculated using the formula below: 
𝐼𝑜𝑛𝑖𝑧𝑎𝑡𝑖𝑜𝑛 𝑆𝑢𝑝𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑟 𝐸𝑛ℎ𝑎𝑛𝑐𝑒𝑚𝑒𝑛𝑡 (%) 𝑎𝑡 𝑎 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
=  (
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑆𝑖𝑔𝑛𝑎𝑙 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝐵𝑙𝑎𝑛𝑘 𝑀𝑎𝑡𝑟𝑖𝑐𝑒𝑠 (𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 𝑡𝑒𝑛)
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑆𝑖𝑔𝑛𝑎𝑙 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝑁𝑒𝑎𝑡 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑
− 1) × 100% 
For a method to be valid, the average signal suppression or enhancement has to be within 




of the suppression or enhancement to other validation parameters (e.g., bias, LOD, LOQ) 
has to be demonstrated, i.e. other parameters have to be within their own acceptable ranges. 
In this study, the two concentrations examined were at 200 and 1500 ng/mL. At 
each concentration, neat standard was injected six times and a total of 10 different matrix-
matched samples fortified with target analyte and IS after extraction were made in duplicate 






Recovery indicates the ability of a method to recover target analyte after extraction. 
It is generally evaluated concurrently with ionization suppression or enhancement by 
comparing the signal responses between blank matrices fortified with target analyte before 
extraction and after extraction. At one of the two concentrations mentioned in Section 5.8, 
blank matrices (at least ten) fortified before extraction are made along with those fortified 
post-extraction. Their average signal response was compared with that of the post-
extraction samples for assessing recovery. The formula for calculating recovery is as 
follow: 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) 𝑎𝑡 𝑎 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
=  (
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑆𝑖𝑔𝑛𝑎𝑙 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝐵𝑙𝑎𝑛𝑘 𝑀𝑎𝑡𝑟𝑖𝑐𝑒𝑠 𝑓𝑜𝑟𝑡𝑖𝑓𝑖𝑒𝑑 𝐵𝐸𝐹𝑂𝑅𝐸 𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑆𝑖𝑔𝑛𝑎𝑙 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝐵𝑙𝑎𝑛𝑘 𝑀𝑎𝑡𝑟𝑖𝑐𝑒𝑠 𝑓𝑜𝑟𝑡𝑖𝑓𝑖𝑒𝑑 𝐴𝐹𝑇𝐸𝑅 𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛
) × 100% 
In this study, at each of the two concentrations (200 and 1500 ng/mL) mentioned 
in Section 5.8, 10 different matrix-matched samples fortified with target analyte and IS 
before and after extraction (in duplicate) were made. A minimum of 50% recovery of target 





6. RESULTS AND DISCUSSION 
6.1 Liquid-Liquid Extraction (LLE) 
6.1.1 Calibration Model, Carryover, and Detection Limits 




) calibration model with six calibrators (20, 50, 150, 500, 1000, and 2000 
ng/mL) was reproducible in both blood and urine with individual and average r2 greater 
than or equal to 0.997 over five separate runs (Table 8). The concentrations for calibrators 
and controls (60, 950 and 1800 ng/mL) calculated against the calibration curve were all 
within ±20% of their expected values. Their ion ratios in each run were also within ±20% 
of the average ion ratio. No carryover was observed for each double blank run immediately 
after the 2000 ng/mL calibrator of the calibration model. Standardized residual plots for 
barbiturates in blood and urine (Figure 16) all showed random distribution of residuals 
around the zero line, which indicate the use of the appropriate linear model. However, for 
butalbital and phenobarbital in blood and urine, some residuals at the high end of the 
calibration model (500, 1000 and 2000 ng/mL) did lie outside ±3 standard deviation of the 
expected value. This suggests re-analysis or adjusting the concentrations of high-end 
calibrators may be needed. LOD evaluated for amobarbital, butalbital, and phenobarbital 
in blood and urine ranged from 5 to 15 ng/mL, while the LOQ was either at 15 or 20 ng/mL 
(Table 9). Overall, the LOD and LOQ for barbiturates in blood was lower than that in urine 





Table 8. Individual and Average r2 for Amobarbital, Butalbital, and Phenobarbital in Blood 
and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Run 1 0.99956 0.99991 0.99853 0.99919 0.99927 0.99885 
Run 2 0.99982 0.99994 0.99877 0.99941 0.99814 0.99827 
Run 3 0.99981 0.99972 0.99949 0.99943 0.99889 0.99818 
Run 4 0.99981 0.99972 0.99949 0.99943 0.99889 0.99818 
Run 5 0.99983 0.99953 0.99917 0.99903 0.99958 0.99797 









Figure 16. Standardized Residual Plots for Amobarbital, Butalbital, and Phenobarbital in 
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Table 9. LOD and LOQ for Amobarbital, Butalbital, and Phenobarbital in Blood and Urine 
Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD (ng/mL) 5 15 10 15 10 15 
LOQ (ng/mL) 15 20 20 15 20 20 
 
6.1.2 Bias and Precision, Stability, and Dilution Integrity 
With the ion ratio within ±20% of the average ion ratio for each control in each run, 
biases for amobarbital, butalbital, and phenobarbital in both matrices were all within ±15%; 
within-run precisions were all smaller than 15%CV; and between-run precisions were all 
less than 10%CV (Table 10-12). The three barbiturates extracted with LLE were also found 
to be stable up to 72 hours at room temperature after initial analysis (T0) based on their 
biases of average response ratio (Table 13). Bias and between-run precision of the diluted 
samples diluted 1:10 (400 ng/mL) and 1:50 (80 ng/mL) in both matrices were within ±15% 
and less than 10%CV, respectively (Table 14 and 15).  
 
Table 10. Bias (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and Urine 
Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (60 ng/mL) -6.18 -4.74 -11.69 -10.38 -7.94 -9.16 
Medium (950 ng/mL) -0.17 -0.88 7.44 4.41 6.43 6.66 






Table 11. Within-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low  
(60 ng/mL) 
Run 1 2.25 1.47 2.29 2.57 2.17 3.63 
Run 2 4.00 2.33 2.28 1.67 5.74 3.62 
Run 3 2.22 2.87 1.63 0.86 3.31 0.36 
Run 4 3.79 3.61 3.06 2.18 5.37 7.10 
Run 5 2.17 2.35 1.13 5.79 3.14 4.08 
Medium  
(950 ng/mL) 
Run 1 2.69 0.69 1.61 1.20 2.30 0.39 
Run 2 0.83 1.29 1.98 2.83 1.76 1.02 
Run 3 0.21 1.15 1.49 0.21 1.46 5.82 
Run 4 2.66 0.64 0.67 1.29 2.06 1.83 
Run 5 0.44 3.35 0.35 3.61 0.70 3.02 
High 
(1800 ng/mL) 
Run 1 1.80 2.75 1.34 2.03 2.12 3.51 
Run 2 1.66 1.25 0.98 0.75 3.53 6.86 
Run 3 0.79 1.01 0.76 1.12 0.90 2.59 
Run 4 0.45 0.63 1.14 1.02 1.28 0.76 
Run 5 0.74 11.16 0.99 9.51 1.60 9.31 
*The highest within-run precision in each run are highlighted 
 
Table 12. Between-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (60 ng/mL) 3.58 3.79 2.85 3.95 4.70 5.40 
Medium (950 ng/mL) 2.51 2.05 1.80 2.69 3.35 4.51 









Table 13. Bias (%) for Average Response Ratio for Amobarbital, Butalbital, and 
Phenobarbital Stability in Blood and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low  
(60 ng/mL) 
T24 2.93 6.85 -5.46 -2.22 -2.59 -0.26 
T48 -5.32 -3.90 -0.07 1.69 -1.36 -2.97 
T72 3.95 4.51 3.21 -2.04 -0.87 1.84 
Medium  
(950 ng/mL) 
T24 -0.64 1.12 0.18 1.28 -6.06 -2.30 
T48 -2.69 -1.10 1.50 1.66 -4.61 -0.87 
T72 2.00 7.71 -1.37 -1.56 -0.40 1.04 
High  
(1800 ng/mL) 
T24 -1.19 1.40 0.68 0.21 -2.17 2.42 
T48 -3.06 1.31 2.37 2.35 -2.27 1.62 
T72 2.21 5.08 -3.80 -1.06 1.24 4.66 
 
Table 14. Bias (%) for Amobarbital, Butalbital, and Phenobarbital Diluted in Blood and 
Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
1:10 (400 ng/mL) 2.31 4.73 9.18 8.91 9.76 12.92 
1:50 (80 ng/mL) -7.10 -3.35 -5.18 -0.63 -4.78 1.01 
 
Table 15. Between-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital 
Diluted in Blood and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
1:10 (400 ng/mL) 3.32 2.56 2.31 2.27 3.47 3.98 
1:50 (80 ng/mL) 6.02 4.91 7.17 5.64 7.50 5.57 
 
6.1.3 Interference Studies 
Amobarbital, butalbital, and phenobarbital extracted from blood and urine using 




tested signal response was higher than the LOD or LOQ responses of the three barbiturates 
(Table 16-18). 
 
Table 16. Matrix Interference for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOQ* 
16714.78 19733.33 20853.33 11831.17 17143.33 17812.22 
15 ng/mL 20 ng/mL 20 ng/mL 15 ng/mL 20 ng/mL 20 ng/mL 
Blank Matrix 1  53.61 10.95 273.10 580.20 40.54 7.67 
Blank Matrix 2 110.50 62.60 170.20 86.15 37.29 63.31 
Blank Matrix 3 38.93 19.27 439.00 97.52 10.96 107.70 
Blank Matrix 4 13.07 171.50 246.10 62.58 79.32 13.11 
Blank Matrix 5 25.84 36.50 63.99 750.60 121.70 131.30 
Blank Matrix 6 67.09 9.57 252.90 159.80 107.60 10.99 
Blank Matrix 7 40.53 20.74 164.00 249.50 13.49 27.05 
Blank Matrix 8 66.77 9.70 163.70 266.50 13.53 13.07 
Blank Matrix 9 26.71 10.99 231.60 33.66 13.51 66.50 
Blank Matrix 10 53.43 40.49 141.00 144.50 40.29 27.02 
Matrix 
Interference? 
No No No No No No 
*All values are signal responses unless otherwise specified 
 
Table 17. Internal Standard Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD* 
5682.50 13527.78 10257.17 11831.17 8136.61 12274.78 
5 ng/mL 15 ng/mL 10 ng/mL 15 ng/mL 10 ng/mL 15 ng/mL 
IS+ 187.40 197.50 44.53 164.70 133.70 13.52 
Highest 
Calibrator^ 
34.32 53.82 51.78 107.70 26.50 12.91 
IS Interference? No No No No No No 
*All values are signal responses unless otherwise specified 
+Signal area of the highest calibrator in matrix-matched sample fortified with IS only 





Table 18. Common Analytes Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD* 
5682.50 13527.78 10257.17 11831.17 8136.61 12274.78 
5 ng/mL 15 ng/mL 10 ng/mL 15 ng/mL 10 ng/mL 15 ng/mL 
Intermix 1 92.15 19.39 159.70 184.20 13.53 269.60 
Intermix 3 6.63 73.76 42.49 53.34 78.92 108.20 




No No No No No No 
*All values are signal responses unless otherwise specified 
6.1.4 Ionization Suppression/Enhancement and Recovery 
Comparing the responses from neat sample (un-extracted barbiturates, including 
IS) to sample fortified with barbiturates after extraction, amobarbital, butalbital, and 
phenobarbital in blood extracted with LLE showed an ionization enhancement effect in 
both concentration levels (200 and 1500 ng/mL). The enhancement effect by blood was 
between 10 to 20% at low concentration, while it was within 5% at high concentration. On 
the contrary, suppression effect was observed for the three barbiturates extracted in urine. 
That matrix effect was between -20% to -30% at low concentration and was within -20% 
at high concentration (Table 19). Although the ionization suppression effect in urine at low 
concentration exceeded the ±25% criteria, it had minimal impact to the analysis since other 
validation parameters for urine mentioned in previous sections all fell under the acceptable 
ranges and each analyte has its own deuterated internal standard. 
Recovery was evaluated as a comparison between the responses of samples fortified 




phenobarbital using LLE demonstrated recoveries 53-68% (Table 20). There was no 
significant difference in recovery between barbiturates in blood or in urine. 
 
Table 19. Ionization Suppression/Enhancement (%) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (200 ng/mL) 11.53 -25.97 12.52 -25.89 15.60 -20.00 
High (1500 ng/mL) 2.39 -17.64 3.06 -15.81 1.07 -15.77 
 
Table 20. Recovery (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and Urine 
Using LLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (200 ng/mL) 61.34 57.41 61.63 60.75 64.13 67.89 







6.2 Supported-Liquid Extraction (SLE) 
6.2.1 Calibration Model, Carryover, and Detection Limits 
The six-point calibration model for amobarbital, butalbital, and phenobarbital 
extracted from blood and urine using SLE was reproducible with individual and average r2 
greater than or equal to 0.994 over five separate runs (Table 21). Concentrations and ion 
ratios of calibrators and controls were all within the ±20% criteria. Carryover was not 
observed throughout the entire SLE validation. Standardized residual plots of barbiturates 
revealed random distribution of residuals around the zero line for both blood and urine 
(Figure 17), indicating the use of a linear model was appropriate. All the residuals were 
within the ±3 standard deviation of the expected value. This shows none of the calibration 
points used were outliers in this model. LOD for barbiturates in blood and urine was found 
to be either 10 ng/mL or 15 ng/mL, while the LOQ ranged from 10 ng/mL to 20 ng/mL 
(Table 22). 
 
Table 21. Individual and Average r2 for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Run 1 0.99821 0.99892 0.99859 0.99980 0.99891 0.99864 
Run 2 0.99846 0.99445 0.99969 0.99869 0.99807 0.99884 
Run 3 0.99920 0.99581 0.99821 0.99974 0.99740 0.99902 
Run 4 0.99642 0.99736 0.99928 0.99555 0.99671 0.99769 
Run 5 0.99933 0.99920 0.99891 0.99891 0.99970 0.99970 







Figure 17. Standardized Residual Plots for Amobarbital, Butalbital, and Phenobarbital in 
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Table 22. LOD and LOQ for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD (ng/mL) 15 10 10 10 10 10 
LOQ (ng/mL) 15 20 10 15 20 15 
 
6.2.2 Bias and Precision, Stability, and Dilution Integrity 
Biases for all three barbiturates in blood and urine were all within ±20%, yet the 
accuracy at low concentration (60 ng/mL) was significantly less satisfactory than at 
medium (950 ng/mL) and high (1800 ng/mL) concentrations (Table 23). Within-run and 
between-run precision all exhibited %CV less than 20% (Table 23-25). For stability, 
barbiturates in blood and urine extracted with SLE were stable up to 72 hours at room 
temperature after initial analysis (T0) (Table 26). Dilution integrity also revealed that 
barbiturates in blood and urine were able to be diluted 1:50 (80 ng/mL).  Bias and between-
run precision of the diluted samples were within ±8% and less than 12%CV, respectively 
(Table 27 and 28). 
 
Table 23. Bias (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and Urine 
Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (60 ng/mL) 17.97 10.14 10.41 14.44 2.74 12.29 
Medium (950 ng/mL) -2.03 -4.36 -3.45 -4.13 -3.96 -5.20 





Table 24. Within-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low  
(60 ng/mL) 
Run 1 8.35 6.83 8.68 3.13 13.79 12.50 
Run 2 11.13 4.23 12.49 2.05 13.18 4.13 
Run 3 0.42 6.91 0.70 8.14 10.57 12.59 
Run 4 19.17 7.10 4.98 4.04 5.26 2.33 
Run 5 11.29 0.42 4.77 5.45 6.62 6.62 
Medium  
(950 ng/mL) 
Run 1 1.17 5.89 4.51 1.82 3.32 3.22 
Run 2 3.90 6.71 7.08 1.12 10.10 2.17 
Run 3 2.51 3.83 11.58 11.57 3.68 13.70 
Run 4 8.77 4.67 5.98 6.52 5.30 3.03 
Run 5 10.54 2.51 0.48 0.48 1.16 1.16 
High 
(1800 ng/mL) 
Run 1 4.48 5.06 2.77 5.31 4.89 7.13 
Run 2 7.05 3.74 8.21 4.49 4.04 3.77 
Run 3 2.75 3.75 7.93 2.15 5.27 2.70 
Run 4 6.49 6.05 3.62 3.79 3.19 9.39 
Run 5 1.07 2.75 0.93 0.93 3.04 3.04 
*The highest within-run precision in each run is highlighted 
 
Table 25. Between-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (60 ng/mL) 16.62 8.46 14.84 11.64 12.97 12.77 
Medium (950 ng/mL) 9.37 6.68 14.92 10.89 9.28 9.55 









Table 26. Bias (%) for Average Response Ratio for Amobarbital, Butalbital, and 
Phenobarbital Stability in Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low  
(60 ng/mL) 
T24 3.80 7.13 4.19 6.80 -4.73 9.88 
T48 1.32 4.51 1.76 -0.14 1.56 4.44 
T72 5.01 2.87 3.02 -1.43 1.50 4.91 
Medium  
(950 ng/mL) 
T24 0.96 -0.05 0.08 -0.67 1.27 4.98 
T48 -1.05 -2.74 -2.89 -1.33 0.59 4.32 
T72 -2.67 -3.91 -4.51 -4.88 4.11 2.00 
High  
(1800 ng/mL) 
T24 5.16 1.32 -0.58 -1.61 3.05 6.99 
T48 -2.36 -3.73 -1.54 -1.11 -2.94 5.85 
T72 1.92 -2.00 -6.22 -4.59 -1.65 3.38 
 
Table 27. Bias (%) for Amobarbital, Butalbital, and Phenobarbital Diluted in Blood and 
Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
1:10 (400 ng/mL) 4.06 7.55 -2.48 4.60 4.69 5.96 
1:50 (80 ng/mL) -4.29 -2.23 -5.03 -1.24 -3.22 5.52 
 
Table 28. Between-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital 
Diluted in Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
1:10 (400 ng/mL) 9.32 4.49 7.19 8.01 7.32 6.56 
1:50 (80 ng/mL) 10.67 6.01 11.89 4.82 10.59 6.81 
 
6.2.3 Interference Studies 
No signal response from matrices, IS, or common analytes tested was found higher 




interference was not observed when extracting barbiturates from blood and urine using 
SLE. 
 
Table 29. Matrix Interference for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOQ* 
12126.61 16870.00 7315.89 10868.00 13864.83 7707.00 
15 ng/mL 20 ng/mL 10 ng/mL 15 ng/mL 20 ng/mL 15 ng/mL 
Blank Matrix 1  13.02 65.03 14.34 84.53 22.80 147.60 
Blank Matrix 2 42.72 13.53 19.35 15.36 49.81 26.67 
Blank Matrix 3 13.23 269.20 27.90 11.01 26.36 13.50 
Blank Matrix 4 38.73 47.98 20.43 64.41 54.05 81.05 
Blank Matrix 5 72.14 85.72 27.16 21.72 12.93 13.50 
Blank Matrix 6 10.95 47.98 23.01 26.03 13.52 40.52 
Blank Matrix 7 26.50 80.09 13.08 13.49 13.25 80.73 
Blank Matrix 8 88.86 46.13 9.57 22.30 67.60 13.49 
Blank Matrix 9 10.95 67.03 67.64 7.43 54.02 40.50 
Blank Matrix 10 66.42 68.81 10.85 13.53 13.52 40.52 
Matrix 
Interference? 
No No No No No No 
*All values are signal responses unless otherwise specified 
 
Table 30. Internal Standard Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD* 
12126.61 9692.78 7315.89 7863.44 6787.28 6604.56 
15 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 
IS+ 68.20 23.80 42.96 29.21 53.23 37.81 
Highest 
Calibrator^ 
114.40 74.13 177.70 268.00 13.52 27.03 
IS Interference? No No No No No No 
*All values are signal responses unless otherwise specified 
+Signal area of the highest calibrator in matrix-matched sample fortified with IS only 





Table 31. Common Analytes Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD* 
12126.61 9692.78 7315.89 7863.44 6787.28 6604.56 
15 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 10 ng/mL 
Intermix 1 93.18 119.90 27.54 41.38 10.95 20.53 
Intermix 3 10.85 11.24 35.26 166.60 12.54 36.72 




No No No No No No 
*All values are signal responses unless otherwise specified 
6.2.4 Ionization Suppression/Enhancement and Recovery 
Ionization enhancement was observed for barbiturates in blood and urine at both 
low and high concentrations. The enhancement by matrices were up to 10%, yet urine 
yielded a slightly greater signal enhancement than blood at both concentration levels (Table 
32). Barbiturates extracted using SLE demonstrated recoveries up to 86%. The three 
barbiturates in urine were consistently found to have higher recoveries than in blood at 
both concentrations (Table 33). However, recoveries of barbiturates from blood were 
below the desired 50% at high concentration. 
 
Table 32. Ionization Suppression/Enhancement (%) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (200 ng/mL) 1.25 4.73 3.40 9.63 7.68 10.00 





Table 33. Recovery (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and Urine 
Using SLE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (200 ng/mL) 52.83 77.03 55.59 74.55 53.34 82.37 







6.3 Solid-Phase Extraction (SPE) 
6.3.1 Calibration Model, Carryover, and Detection Limits 
Six-point calibration model was also reproducible for the extraction of amobarbital, 
butalbital, and phenobarbital in blood and urine using SPE. The individual and average r2 
were greater than or equal to 0.996 over all five runs (Table 34). Concentrations and ion 
ratios calculated all met the ±20% criteria. Carryover was not detected throughout the entire 
validation. Residuals in standardized residual plots were all randomly distributed around 
the zero line (Figure 18), thus indicating the use of a linear model. However, a few of the 
butalbital and phenobarbital residuals at the high end of the calibration model (500, 1000, 
and 2000 ng/mL) were found outside the ±3 standard deviation limit. Re-analysis or 
method adjustment might be needed to improve the reliability of the calibration model. 
LOD and LOQ for barbiturates in blood and urine were either 15 or 20 ng/mL (Table 35). 
The limits of detection for blood were found to be equal to or lower than that of the urine. 
 
Table 34. Individual and Average r2 for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Run 1 0.99961 0.99980 0.99944 0.99913 0.99974 0.99889 
Run 2 0.99979 0.99914 0.99980 0.99947 0.99993 0.99945 
Run 3 0.99926 0.99621 0.99993 0.99796 0.99961 0.99757 
Run 4 0.99952 0.99936 0.99982 0.99919 0.99970 0.99932 
Run 5 0.99961 0.99992 0.99980 0.99924 0.99981 0.99986 






Figure 18. Standardized Residual Plots for Amobarbital, Butalbital, and Phenobarbital in 
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Table 35. LOD and LOQ for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD (ng/mL) 15 15 15 20 15 20 
LOQ (ng/mL) 15 20 15 20 20 20 
 
6.3.2 Bias and Precision, Stability, and Dilution Integrity 
Biases and within-run precisions for barbiturates in blood and urine were within 
±15% and less than 15%CV, respectively. Between-run precisions were less than 20%CV 
(Table 36-38), yet barbiturates in blood were found to have lower between-run precisions 
than in urine. Similar to LLE and SLE, barbiturates extracted using SPE were stable up to 
72 hours at room temperature after initial analysis (T0) (Table 39). Barbiturates in blood 
and urine were also able to be diluted 1:50 (80 ng/mL) since bias and between-run precision 
of the diluted samples were within ±20% and less than 15%CV, respectively (Table 40 and 
41). 
 
Table 36. Bias (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and Urine 
Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (60 ng/mL) 2.03 3.81 7.44 -2.26 5.72 0.26 
Medium (950 ng/mL) -4.42 -9.67 -4.41 -2.69 -5.09 -2.57 






Table 37. Within-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low  
(60 ng/mL) 
Run 1 3.87 2.91 3.64 2.36 4.63 8.40 
Run 2 5.48 11.18 1.92 4.01 5.71 6.69 
Run 3 6.00 6.96 5.19 4.01 3.87 6.63 
Run 4 3.54 0.79 3.07 1.44 2.09 8.33 
Run 5 7.11 3.76 1.23 1.20 3.33 3.40 
Medium  
(950 ng/mL) 
Run 1 0.87 9.69 1.27 12.27 2.36 1.83 
Run 2 2.66 6.12 2.16 3.20 2.85 6.69 
Run 3 3.33 0.92 2.17 1.29 2.37 1.34 
Run 4 0.54 4.35 2.04 3.60 1.71 7.63 
Run 5 1.83 4.02 2.43 1.13 2.55 4.62 
High 
(1800 ng/mL) 
Run 1 1.06 13.31 3.09 8.30 1.49 1.72 
Run 2 2.39 4.42 4.76 4.69 3.52 1.47 
Run 3 3.77 1.66 4.37 4.91 2.06 5.91 
Run 4 1.32 5.30 3.52 2.73 2.60 2.47 
Run 5 2.61 1.63 3.27 2.24 2.74 2.66 
*The highest within-run precision in each run is highlighted 
 
Table 38. Between-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (60 ng/mL) 7.20 8.56 4.35 8.35 5.78 17.29 
Medium (950 ng/mL) 3.02 7.39 2.22 9.06 2.78 6.68 










Table 39. Bias (%) for Average Response Ratio for Amobarbital, Butalbital, and 
Phenobarbital Stability in Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low  
(60 ng/mL) 
T24 -9.37 8.74 -1.63 2.65 -7.46 -10.07 
T48 9.83 -5.87 5.07 3.05 -13.94 -13.60 
T72 -7.59 -6.28 -6.05 1.43 -18.23 -8.28 
Medium  
(950 ng/mL) 
T24 -2.89 -11.25 4.04 2.44 -3.60 -9.83 
T48 11.59 -6.41 6.02 1.52 -5.81 -6.92 
T72 -0.64 -7.03 2.46 -1.39 -4.78 -6.68 
High  
(1800 ng/mL) 
T24 -2.74 -8.67 4.03 0.40 3.13 -9.09 
T48 4.96 -5.58 4.44 -0.88 2.58 -8.04 
T72 -0.48 -2.07 6.89 -0.14 3.78 -6.18 
 
Table 40. Bias (%) for Amobarbital, Butalbital, and Phenobarbital Diluted in Blood and 
Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
1:10 (400 ng/mL) -5.99 -6.06 4.10 3.16 -7.56 3.17 
1:50 (80 ng/mL) 6.65 -4.02 16.22 5.57 11.32 -4.60 
 
Table 41. Between-Run Precision (%CV) for Amobarbital, Butalbital, and Phenobarbital 
Diluted in Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
1:10 (400 ng/mL) 5.78 6.28 6.19 11.23 6.75 5.21 
1:50 (80 ng/mL) 6.36 8.23 4.95 9.15 5.58 8.75 
 
6.3.3 Interference Studies 
Signal responses from matrices, IS, or common analytes tested were all below that 
of the barbiturates LOD or LOQ (Table 42-44). Therefore, no significant interference was 




Table 42. Matrix Interference for Amobarbital, Butalbital, and Phenobarbital in Blood and 
Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOQ* 
10296.39 4977.33 8092.50 3341.61 4249.83 2308.56 
15 ng/mL 20 ng/mL 15 ng/mL 20 ng/mL 20 ng/mL 20 ng/mL 
Blank Matrix 1  135.40 54.11 80.17 26.55 10.89 62.47 
Blank Matrix 2 10.83 13.26 53.79 416.90 39.27 66.33 
Blank Matrix 3 77.17 13.55 74.16 80.93 27.00 26.79 
Blank Matrix 4 334.40 27.06 88.33 54.45 39.43 13.53 
Blank Matrix 5 84.78 13.50 67.48 27.00 16.80 40.56 
Blank Matrix 6 52.11 13.52 10.97 13.53 40.09 13.53 
Blank Matrix 7 134.50 13.50 136.70 40.55 26.42 40.58 
Blank Matrix 8 539.20 27.05 220.70 599.90 50.25 13.51 
Blank Matrix 9 582.70 13.51 116.10 67.56 167.90 13.53 
Blank Matrix 10 48.89 20.68 47.75 53.19 21.66 94.90 
Matrix 
Interference? 
No No No No No No 
*All values are signal responses unless otherwise specified 
 
Table 43. Internal Standard Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD* 
10296.39 3269.56 8092.50 3341.61 3396.56 2308.56 
15 ng/mL 15 ng/mL 15 ng/mL 20 ng/mL 15 ng/mL 20 ng/mL 
IS+ 121.10 71.42 12.94 51.73 138.10 15.29 
Highest 
Calibrator^ 
105.40 44.95 36.62 45.27 125.20 23.68 
IS Interference? No No No No No No 
*All values are signal responses unless otherwise specified 
+Signal area of the highest calibrator in matrix-matched sample fortified with IS only 








Table 44. Common Analytes Interference for Amobarbital, Butalbital, and Phenobarbital in 
Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LOD* 
10296.39 3269.56 8092.50 3341.61 3396.56 2308.56 
15 ng/mL 15 ng/mL 15 ng/mL 20 ng/mL 15 ng/mL 20 ng/mL 
Intermix 1 54.11 14.36 37.50 143.40 27.05 111.80 
Intermix 3 27.04 1.52 81.48 59.77 27.05 39.56 




No No No No No No 
*All values are signal responses unless otherwise specified 
6.3.4 Ionization Suppression/Enhancement and Recovery 
Barbiturates extracted from blood and urine using SPE exhibited the most 
ionization suppression. For most analytes, values were within 25%, yet signal responses of 
barbiturates extracted from urine were suppressed by over 70% (Table 45). Although the 
matrix effect was substantial, analysis using SPE was only subjected to minimal impact as 
each analyte had its own deuterated internal standard and other validation parameters were 
all acceptable. For recovery, SPE was able to recover over 50% in blood and; up to 70% 
of barbiturates from urine. However, recovery of barbiturates from blood was closer to 
50% (Table 46). 
 
Table 45. Ionization Suppression/Enhancement (%) for Amobarbital, Butalbital, and 
Phenobarbital in Blood and Urine Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (200 ng/mL) -23.28 -71.24 -24.68 -79.92 -27.87 -83.88 




Table 46. Recovery (%) for Amobarbital, Butalbital, and Phenobarbital in Blood and Urine 
Using SPE 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
Low (200 ng/mL) 46.31 70.30 47.73 72.61 51.42 69.07 










Apart from validating different sample preparation methods, the purpose of this 
study is to also compare the efficiency and effectiveness of LLE, SLE, and SPE, thus to 
recommend the most suitable method to recover barbiturates from blood and urine under 
the laboratory setting at BUMC. Efficiency evaluates the time and ease of a method to 
extract target analyte, while effectiveness is an assessment of one’s ability to selectively 
recover target analyte at a reasonably low concentration. 
 
7.1 Efficiency 
Among the three extraction methods investigated, LLE and SPE required the 
longest time to prepare samples for instrumental analysis, which was approximately 4 
hours. The time for SLE to finish the overall pretreatment and extraction for roughly 36-
48 samples was only 2-3 hours. The major reason LLE was more time-consuming was the 
involvement of the manual transfer step. Physical separation of target analyte was still 
needed even after the 3-step LLE in one single container. Training is therefore required as 
it takes time for the analyst to master the hand-eye coordination for separating the 
immiscible layers (Table 47).8 When the number of samples go up and no automation is 
available, LLE can take a long time to complete. This is the reason why LLE is commonly 
known as labor intensive.7 
Solid-phase extraction in this study was also more time intensive than SLE. It was 




used for conditioning, almost an hour waiting was needed to evaporate the eluate to dryness 
and to proceed to reconstitution. Although it took time for evaporation, the entire process 
only involved 2-3 steps and is actually amenable to automation. Therefore, only minimal 
training is needed for analyst (Table 47). 
Among the three sample preparation methods, SLE took the least amount of time, 
which was only 2-3 hours. It did not require manual transfer and required much less drying 
time due to the use of organic solvents. There was also no solvent waste at all when 
compared to LLE and SPE. The 3-step procedure can be automated as well so only minimal 
training is required (Table 47). Based on the comparison, SLE was the most efficient 
sample preparation method among the three for the extraction of barbiturates in blood and 
urine under the laboratory setting at BUMC, however, a method’s effectiveness still needs 
to be considered in order to determine the most efficient and effective method for 
quantifying a specific barbiturate in a particular matrix. 
 
Table 47. Comparison of the Efficiency of LLE, SLE, and SPE 
 LLE SLE SPE 
Time ~ 4 hours 2-3 hours ~ 4 hours 
Number of Extraction Steps 4* 3^ 3+ 
Number of Solvents 3 2 3 
Automatable? No Yes Yes 
Training Required? Yes Minimal Minimal 
*1) Addition of Extraction Solvent 2) Rock 3) Centrifuge 4) Transfer of Organic Layer 
^1) Sample Load 2) Wait 3) Elute 







For quantitation of amobarbital in blood, LLE offered the highest drug recovery, 
while the recoveries for SLE and SPE did not meet the minimum expectation of 50%. LLE 
also provided a more accurate and precise detection with LOD down to 5 ng/mL, the lowest 
among the three methods. SLE, in contrast, provided the best results for the extraction of 
amobarbital in urine. Not only was it able to recover up to 86% of amobarbital, it also 
yielded the cleanest extract and demonstrated the least amount of matrix effects. SLE had 
the lowest LOD among the three methods as well (Table 48). 
Quantifying butalbital in blood was the best using either LLE or SLE. LLE offered 
a recovery over 60%, while SLE provided a recovery around 50% but with a cleaner extract 
and lower LOQ. If recovery is highly desired over the quantification limit, SLE is 
recommended. Quantitation of butalbital in urine was the most effective using SLE because 
recovery was up to 80% with low matrix effect, unlike LLE and SPE which suffered from 
ionization suppression (Table 49). LOD was able be go as low as 10 ng/mL as well when 
using SLE. 
Similar to amobarbital, LLE and SLE were the most effective methods for 
quantifying phenobarbital in blood and urine, respectively. LLE offered the highest 
recovery among the three methods with decent extract cleanliness for the blood extraction. 
Samples extracted via SLE, in this case, had recovery values barely reaching 50%, while 
samples extracted via SPE partly suffered from matrix effect. For the quantification in urine, 




great extract cleanliness; and reaching the lowest level of LOD and LOQ among the tested 
methods (Table 50). 
Although SLE was the most efficient sample preparation method for extracting 
barbiturates in this study, LLE was the most effective at quantifying barbiturate in blood, 
while SLE was the most suitable for barbiturates from urine under the setting in the 
laboratory. Table 51 illustrates the sample preparation method recommended for extracting 









Table 48. Comparison of Effectiveness of LLE, SLE, and SPE in Extracting Amobarbital from Blood and Urine 
 
LLE SLE SPE 
Blood Urine Blood Urine Blood Urine 
Recovery 59-61% 57-62% 46-52% 77-86% ~45% 63-70% 
Extract Cleanliness* +12% -26% +3% +5% -23% -71% 
LOD 5 ng/mL 15 ng/mL 15 ng/mL 10 ng/mL 15 ng/mL 15 ng/mL 
LOQ 15 ng/mL 20 ng/mL 15 ng/mL 20 ng/mL 15 ng/mL 20 ng/mL 
Reproducibility^ < ±7% < ±12% < ±20% < ±11% < ±8% < ±14% 
*Evaluated by the largest Matrix Effect 
^Evaluated by Overall Bias and Precision 
 
Table 49. Comparison of Effectiveness of LLE, SLE, and SPE in Extracting Butalbital from Blood and Urine 
 
LLE SLE SPE 
Blood Urine Blood Urine Blood Urine 
Recovery 55-61% 55-61% 48-55% 74-80% ~48% 56-72% 
Extract Cleanliness* +13% -26% +4% +10% -25% -80% 
LOD 10 ng/mL 15 ng/mL 10 ng/mL 10 ng/mL 15 ng/mL 20 ng/mL 
LOQ 20 ng/mL 15 ng/mL 10 ng/mL 15 ng/mL 15 ng/mL 20 ng/mL 
Reproducibility^ < ±12% < ±11% < ±15% < ±15% < ±8% < ±13% 
*Evaluated by the largest Matrix Effect 









Table 50. Comparison of Effectiveness of LLE, SLE, and SPE in Extracting Phenobarbital from Blood and Urine 
 
LLE SLE SPE 
Blood Urine Blood Urine Blood Urine 
Recovery 57-64% 53-68% 47-53% ~82% 48-51% 54-69% 
Extract Cleanliness* +16% -20% +8% +10% -28% -84% 
LOD 10 ng/mL 15 ng/mL 10 ng/mL 10 ng/mL 15 ng/mL 20 ng/mL 
LOQ 20 ng/mL 20 ng/mL 20 ng/mL 15 ng/mL 20 ng/mL 20 ng/mL 
Reproducibility < ±8% < ±10% < ±14% < ±14% < ±6% < ±18% 
*Evaluated by the largest Matrix Effect 
^Evaluated by Overall Bias and Precision 
 
Table 51. Recommendations of Sample Preparation Method for the Extraction of Barbiturates from Blood and Urine 
 
Amobarbital Butalbital Phenobarbital 
Blood Urine Blood Urine Blood Urine 
LLE       
SLE       






8.1 Summary and Significance of Findings 
The first objective of this study was to validate LLE, SLE, and SPE for the 
quantitation of amobarbital, butalbital, and phenobarbital in blood and urine using LC-
MS/MS. As demonstrated in Section 6, the six-point linear calibration model (20, 50, 150, 
500, 1000 and 2000 ng/mL) with inversely weighted concentration (
1
𝑥
) was reproducible in 
all three sample preparation methods for both blood and urine with r2 greater than or equal 
to 0.994. Bias and precision evaluated from low, medium, and high controls (60, 950 and 
1800 ng/mL) were all within ±20% and ±20% CV, respectively. Neither carryover nor 
interference from matrix, IS or common analytes were observed throughout the entire 
validation and the detection limits (LOD and LOQ) were evaluated down to 5 ng/mL. 
Samples can be diluted 1:50 prior to instrumental analysis. Previously injected samples 
were stable at room temperature for up to 72 hours before re-analysis. Recovery of 
barbiturates from blood and urine using LLE, SLE, and SPE all ranged from 45% to 86%, 
whilst the entire study was only subject to minimal impact by the effect of ionization 
suppression or enhancement. Having met the ASB validation guidelines, this study has 
successfully validated three sample preparation methods (LLE, SLE, and SPE) for the 
quantitation of three barbiturates (amobarbital, butalbital, and phenobarbital) in blood and 
urine using LC-MS/MS. 
With three extraction methods available, the second objective of this study was to 




efficiency and effectiveness. Efficiency is an evaluation of time required and ease of a 
method to extract a target analyte. As shown in Section 7.1, SLE was the most efficient 
method for extracting barbiturates under the setting at BUMC laboratory as it required the 
least amount of time to perform due to short drying time, least number of solvents, and the 
absence of a manual transfer step. Its procedure can be easily automated as well so only 
minimal training was required. Effectiveness is another crucial factor for determining the 
most suitable sample preparation method for a particular barbiturate. Based on the 
consideration of each methods’ recovery, extract cleanliness, detection limits, and 
reproducibility, LLE was over overall the most successful at quantitating barbiturates in 
blood and SLE was the most suitable for barbiturates in urine under the laboratory setting 
at BUMC. 
Since this study constitutes part of the BUMC collaborative project with RTI, all 
the analytical data collected have been already reported to RTI, which completed the third 
objective of this study. These findings can be used for interlaboratory comparison and for 
examining the overall reliability and reproducibility of methods. Results obtained can then 
be used to explore the possibility of streamlining sample preparation in the forensic 






8.2 Future Directions 
To provide a more comprehensive comparison, future studies can consider 
increasing the diversity of drugs analyzed. This can be done by including more common 
barbiturates for analysis, such as pentobarbital, secobarbital, and butabarbital, etc. More 
sample preparation methods can also be included for comparison. For example, traditional 
SPE using a UCT cartridge can be included and compared to the data obtained from Waters 
SPE cartridge in this study. A novel extraction method, such as disposable pipette 
extraction, can also be studied to offer a more complete comparison. Increasing the number 
of different biological matrices is also an option. Oral fluid is a good third matrix to be 
included as the demand for toxicological analysis on oral fluid has grown in recent years 
due to its ease of collection and the prevalence of roadside screening.8 Finally, to increase 
the reliability of this collaborative study, data from authentic case samples using those 
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